Not available
Quote | Aevi Genomic Medicine Inc. (NASDAQ:GNMX)
Last: | $ |
---|---|
Change Percent: | 0.00% |
Open: | $N/A |
Close: | $0.1659 |
High: | $N/A |
Low: | $N/A |
Volume: | 0 |
Last Trade Date Time: | 02/12/2020 04:27:58 pm |
News | Aevi Genomic Medicine Inc. (NASDAQ:GNMX)
Cerecor's (CERC) wholly-owned subsidiary, Aevi Genomic Medicine (GNMX) has entered into an expanded agreement with Kyowa Kirin (KYKOF), for exclusive worldwide rights to develop, manufacture and commercialize CERC-002 monoclonal antibody for all indications. Under the terms of agreement, Kyow...
-Cerecor Emerges as a Leading Biopharmaceutical Company in Rare Pediatric and Orphan Diseases -Mike Cola Named Chief Executive Officer and Dr. Garry Neil Named Chief Medical Officer ROCKVILLE, Md., Feb. 03, 2020 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceu...
Message Board Posts | Aevi Genomic Medicine Inc. (NASDAQ:GNMX)
Subject | By | Source | When |
---|---|---|---|
Thats what it is so far thats what | Mrvince | investorshub | 02/05/2020 4:00:30 AM |
i unfortunately did not know that. thank you | StocktonCA | investorshub | 02/05/2020 3:38:10 AM |
Good news did you read what the shares | Mrvince | investorshub | 02/05/2020 12:40:41 AM |
HALTED!!! bc of MERGER!!!! Good News folks!!!!! | StocktonCA | investorshub | 02/04/2020 2:38:07 PM |
https://www.barchart.com/stocks/quotes/$GNMX/opinion | Chrisny73 | investorshub | 01/25/2020 5:55:54 PM |
News, Short Squeeze, Breakout and More Instantly...
Aevi Genomic Medicine Inc. Company Name:
GNMX Stock Symbol:
NASDAQ Market:
Aevi Genomic Medicine Inc. Website:
-Cerecor Emerges as a Leading Biopharmaceutical Company in Rare Pediatric and Orphan Diseases -Mike Cola Named Chief Executive Officer and Dr. Garry Neil Named Chief Medical Officer ROCKVILLE, Md., Feb. 03, 2020 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceu...
GAITHERSBURG, Md., Dec. 16, 2019 (GLOBE NEWSWIRE) -- NexImmune, a clinical-stage biopharmaceutical company developing novel immune-therapeutics based on a proprietary Artificial Immune Modulation (AIM) nanotechnology platform, announced that Sol Barer, PhD has been appointed as the Company&...
-Expands Clinical-stage Pipeline, Further Positioning Cerecor as a Leader in Rare and Orphan Diseases -Enhances Leadership Team with the Addition of Chief Executive Officer and Chief Medical Officer -Strategic Alternatives Being Explored for Neurological Assets and Millipred ...